银屑病关节炎患者接受TNFi治疗中疼痛与疲劳对健康相关生活质量及工作的影响:多国真实世界研究
该多国真实世界研究分析了13个国家640例接受TNFi≥3个月的银屑病关节炎(PsA)患者,发现仍有相当比例患者存在中重度疼痛或疲劳,且疼痛与疲劳严重程度与健康相关生活质量(HRQoL)及工作生产力(WPAI)显著相关(p<0.0001),提示TNFi治疗下疼痛和疲劳仍存在未满足需求。
要点
- 接受TNFi治疗的PsA患者中,33.1%无疼痛、29.2%中度疼痛、37.7%重度疼痛。
- 疲劳方面31.9%为低度、22.5%中度、45.6%重度。
- 中重度疼痛或疲劳者的HRQoL和WPAI显著差于低疼痛或低疲劳者(p<0.0001)。
核心结论
- 尽管使用TNFi等生物制剂,PsA患者中仍有显著疼痛和/或疲劳持续存在,且与HRQoL、身体功能和工作生产力下降显著相关。
- 研究提示PsA治疗领域存在对额外疗法的未满足需求。
研究设计与样本
- 多国真实世界研究,分析来自13个国家的数据。
- 纳入640例接受TNFi≥3个月且完成SF-36v2躯体疼痛和活力域问卷的PsA患者。
主要发现
- 640例患者中33.1%无疼痛、29.2%中度疼痛、37.7%重度疼痛,31.9%低度疲劳、22.5%中度疲劳、45.6%重度疲劳。
- HRQoL各变量和WPAI评分在疼痛和疲劳组间差异均显著(p<0.0001),中重度疼痛或疲劳者的HRQoL和WPAI指标明显更差。
关键数值与推荐
- 疼痛分组:无疼痛33.1%、中度疼痛29.2%、重度疼痛37.7%。
- 疲劳分组:低度疲劳31.9%、中度疲劳22.5%、重度疲劳45.6%。
- HRQoL与WPAI在疼痛和疲劳组间比较的P值均<0.0001。
临床怎么用
- 临床评估PsA患者时应同时关注疼痛和疲劳,即使正在使用TNFi。
- 中重度疼痛或疲劳可能提示HRQoL、身体功能和工作生产力受损,需考虑调整治疗策略。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVE: The incidence of pain and/or fatigue in people with psoriatic arthritis (PsA) is associated with reduced health-related quality of life (HRQoL) and the ability to work, despite modern advanced therapeutic approaches. This real-world, international study examined these relationships in patients with PsA treated with tumour necrosis factor inhibitors (TNFi). METHODS: Data from 13 countries were analysed. Patients with PsA and their physicians completed questionnaires capturing demographics, current therapy, current disease status, HRQoL and work status via Medical Outcomes Study 36-Item Short-Form version 2 (SF-36v2), 3-level 5-dimension EuroQoL questionnaire, Health Assessment Questionnaire Disability Index, and Work Productivity and Activity Impairment (WPAI) questionnaire. RESULTS: 640 patients with PsA were included who had been receiving TNFi for ≥3 months and had completed SF-36v2 bodily pain and vitality domains. Of these, 33.1%, 29.2% and 37.7% of patients reported no, moderate and severe pain, respectively, and 31.9%, 22.5% and 45.6% of patients reported low, moderate and severe fatigue, respectively. Scores across HRQoL variables and WPAI were significantly different across pain and fatigue cohorts (all p<0.0001), with HRQoL and WPAI measures considerably worse in patients with moderate to severe pain or fatigue than those with low pain or fatigue. CONCLUSIONS: Despite treatment with biologic agents such as TNFi, data from this global study demonstrated that substantial pain and/or fatigue persist in patients with PsA and that these are significantly associated with reduced HRQoL, physical function and work productivity. These findings suggest that there is an unmet need for additional PsA therapies.
引用
- Conaghan PG, Alten R, Deodhar A, et al. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open. 2020. PMID: 32611650. doi:10.1136/rmdopen-2020-001240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。